Patent
SYR-DPP-IV-5004-C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Jun Feng et al.

Serial No.: 10/809,636

Filed: March 24, 2004

For: DIPEPTIDYL PEPTIDASE INHIBITORS

Group Art Unit: 1614

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 CFR §§ 1.97 and 1.98, the items identified in this Information Disclosure Statement ("IDS") are brought to the attention of the Office. The items are listed on the attached form PTO-1449, and copies are included for the Examiner's convenience. As the Office no longer requires copies of U.S. patents and applications, the U.S. copies are not being submitted with this IDS. However, if the Examiner would like copies of the U.S. cited references, Applicants will provide the references upon request. The item listed on the attached form PTO-1449 at "EN" is a non-English language article. In accordance with 37 CFR § 1.98(a)(3)(i), the following is a concise explanation of the relevance of this article:

> The article by P.O. Bezuglyi relates to the synthesis of arylsulfonyl hydrazides of 3-R-quinazolone-4-carbonyl-2-acid.

The items identified in this IDS may or may not be "material" pursuant to 37 CFR § 1.56. The submission thereof by Applicant is not to be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR § 1.97(h)), or even qualifies as "prior art" under 35 USC § 102 with respect to this invention unless specifically designated by Applicants as such.

INFORMATION DISCLOSURE STATEMENT FILING PROVISION:

☒ This IDS is believed to be timely in that it is being submitted under 37 CFR § 1.97(b), that is (1) within three months of the filing date of the application, which is not a continued prosecution application filed under § 1.53(d); or (2) within three months of entry of the national stage as set forth in 37 CFR § 1.491; or (3) before the mailing of a first Office action on the merits; or (4) before the mailing of a first Office action after filing a request for continued examination under § 1.114. Thus, no fee is required.

- ☒ However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and charge the fee due under 37 CFR §1.17(p) to the deposit account referenced below.
- ☐ However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and a statement under 37 CFR § 1.97(e) is included below, thus no fee is required.

☐ This IDS is being submitted under 37 CFR § 1.97(c), that is after mailing of a first Office action on the merits, but before a Final Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR § 1.311.

- ☐ The fee due under 37 CFR § 1.17(p) is submitted herewith.
- ☐ A statement under 37 CFR § 1.97(e) is included below, thus no fee is required. In the event that this IDS is not received before a Final Action or a Notice of Allowance, then Applicant respectfully requests that the Office consider the filing of these papers to be submitted under 37 CFR § 1.97(d) and charge the fee due under 37 CFR § 1.17(p) to the deposit account below.

☐ This IDS is being submitted under 37 CFR § 1.97(d), that is after a Final Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR § 1.311, but before payment of the issue fee. A statement under 37 CFR § 1.97(e) is included below. The fee due under 37 CFR § 1.17(p) is submitted herewith.

STATEMENT UNDER 37 CFR § 1.97(e):

☐ Each item contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS.

☐ No item contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing

this statement after making reasonable inquiry, no item of information contained in this IDS was known to any individual designated in 37 CFR § 1.56(c) more than three months prior to the filing of this IDS.

PAYMENT AND/OR AUTHORIZATION TO CHARGE FEES:

☐ A check in the amount of _____ is enclosed for the above fee(s).

☐ Please charge to Deposit Account No. **50-2256** for the above fee(s).

Although Applicants do not believe any fees are required, the Commissioner is authorized to charge any fees required by the filing of these papers to Syrrx's Deposit Account No. **50-2256**.

Respectfully submitted,

SYRRX, INC.

Dated: February 18, 2005 By: _____
David J. Weitz
Reg. No. 38,362

Customer No. **32793**
Syrrx, Inc.
10410 Science Center Drive
San Diego, CA 92121
Tel: (858) 622-8528
Fax: (858) 550-0992

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 10

Complete if Known	
Application Number	10/809,636
Filing Date	March 24, 2004
First Named Inventor	Jun Feng
Group Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	SYR-DPP-IV-5004-C1

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No.[1]	Document Number: Number - Kind Code[2] (*if known*)	Publication Date/ Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US1974/3823135	07-09-1974	Pilgram et al.	
	AB	US1996/5512549	04-30-1996	Chen et al.	
	AC	US1996/5580979	12-03-1996	Bachovchin	
	AD	US1997/5614492	03-25-1997	Habener	
	AE	US2000/6156739	12-5-2000	Griffin et al.	
	AF	US2000/6166063	12-26-2000	Villhauer	
	AG	US2001/6258597-B1	07-10-2001	Bachovchin	
	AH	US2001/0020006-A1	09-06-2001	Demuth et al.	
	AI	US2001/6303661-B1	10-16-2001	Demuth et al.	
	AJ	US2001/6319893-B1	11-20-2001	Demuth et al.	
	AK	US2001/0051646-A1	12-13-2001	Demuth et al.	
	AL	US2002/0049153-A1	04-25-2002	Bridon et al.	
	AM	US2002/0049164-A1	04-25-2002	Demuth et al.	
	AN	US2002/6380398-B2	04-30-2002	Kanstrup et al.	
	AO	US2002/0082427-A1	06-27-2002	Demuth et al.	
	AP	US2002/6448045-B1	09-10-2002	Levine et al.	
	AQ	US2002/0198242-A1	12-26-2002	Demuth et al.	
	AR	US2002/0198380-A1	12-26-2002	Belzer et al.	
	AS	US2002/6500804-B2	12-31-2002	Demuth et al.	
	AT	US2003/0008925-A1	01-09-2003	Demuth et al.	
	AU	US2003/6548481-B1	04-15-2003	Demuth et al.	
	AV	US2003/0092630-A2	05-15-2003	Demuth et al.	
	AW	US2003/0119750-A1	06-26-2003	Demuth et al.	
	AX	US2003/0130199-A1	07-10-2003	von Hoersten et al.	
	AY	US2003/0134802-A1	07-17-2003	Demuth et al.	
	AZ	US2003/0135023-A1	07-17-2003	Demuth et al.	
	BA	US2003/0148961-A1	08-07-2003	Heiser et al.	
	BB	US2003/0153509-A1	08-14-2003	Bachovchin et al.	
	BC	US2003/0162820-A1	08-28-2003	Demuth et al.	
	BD	US2003/0166578-A1	09-04-2003	Arch et al.	
	BE	US2003/6620910-B1	09-16-2003	Calas et al.	
	BF	US2003/0176357-A1	09-18-2003	Pospisilik et al.	
	BG	US2003/0199451-A1	10-23-2003	Mogensen et al.	
	BH	US2003/0199672-A1	10-23-2003	Knudsen et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 10

Complete if Known	
Application Number	10/809,636
Filing Date	March 24, 2004
First Named Inventor	Jun Feng
Group Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	SYR-DPP-IV-5004-C1

	BI	US2003/0236272-A1	12-25-2003	Richard David Carr	
	BJ	US2004/6703238-B2	03-09-2004	Bachovchin	
	BK	US2004/0054171-A1	03-18-2004	Jensen et al.	
	BL	US2004/0058876-A1	03-25-2004	Hoffmann et al.	
	BM	US2004/0132732-A1	07-08-2004	Han et al.	
	BN	US2004/0167191-A1	08-26-2004	Demuth et al.	
	BO	US2004/0171555-A1	09-02-2004	Demuth et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] - Number[4] - Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	BP	FR 2.162.106 (English Abstract-1973)	11-30-1972	Amschler et al.		
	BQ	WO 89/10701	11-16-1989	BASF		
	BR	EP 0378255-A2	07-18-1990	Janssen Pharmaceutica		
	BS	GB 2230527-A	10-24-1990	Imperial Chemical Industries Plc		
	BT	WO 91/12001	08-22-1991	Merck & Co., Inc.		
	BU	WO 93/21162	01-28-1993	Nissan Chemical Industries, Ltd.		
	BV	WO 93/08259 (A2)	04-29-1993	New England Medical Center Hospitals, Inc.		
	BW	WO 93/08259 (A3)	04-29-1993	New England Medical Center Hospitals, Inc.		
	BX	EP 0547442-A1	06-23-1993	E.R. Squibb & Sons, Inc.		
	BY	WO 94/03055	02-17-1994	U.S. Government, Secty. HHS		
	BZ	EP 0587377-A2	03-16-1994	Eli Lilly and Company		
	CA	WO 95/35031	12-28-1995	La Trobe University		
	CB	WO 96/32384	10-17-1996	Taiho Pharmaceutical Co., Ltd.		
	CC	WO 96/38550	12-05-1996	Dana-Farber Cancer Institute, Inc.		
	CD	WO 97/40832	11-06-1997	Hans-Knoll-Institut Fur Naturstoff		
	CE	JP 9295977	11-18-1997	Terumo Corp.		
	CF	WO 98/00439	01-08-1998	Trustees of Tufts College		
	CG	WO 98/24780	06-11-1998	Amgen Inc.		
	CH	WO 99/16864	04-08-1999	Point Therapeutics, Inc.		
	CI	WO 99/38501	08-05-1999	Trustees of Tufts University		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 10

Complete if Known	
Application Number	10/809,636
Filing Date	March 24, 2004
First Named Inventor	Jun Feng
Group Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	SYR-DPP-IV-5004-C1

	CJ	WO 99/50249	10-07-1999	Du Pont Pharmaceuticals Company		
	CK	WO 99-61431	12-02-1999	Probiodrug		
	CL	WO 99/67278	12-29-1999	Pro-Biodrug		
	CM	WO 99/67279	12-29-1999	Pro-Biodrug		
	CN	WO 00/07617	02-17-2000	Novo Nordisk		
	CO	WO 00/09666	02-24-2000	U.S. Government, Secty. HHS		
	CP	WO 00/15211	03-23-2000	Akesis Pharmaceuticals, Inc.		
	CQ	WO 00/76986-A1	04-11-2000	Probiodrug		
	CR	WO 00/34241	06-15-2000	Novartis AG		
	CS	WO 00/47219	08-17-2000	Ontogeny, Inc.		
	CT	WO 00/53171	09-14-00	Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A.		
	CU	WO 00/57721	10-05-2000	Akesis Pharmaceuticals, Inc.		
	CV	WO 01/14318-A2	03-01-2001	Probiodrug		
	CW	WO 01/34594-A1	05-17-2001	Guilford Pharmaceuticals, Inc.		
	CX	WO 01/52825-A2	07-26-2001	Novartis AG		
	CY	WO 01/56988-A1	08-09-2001	Kirin Beer Kabaushiki Kaisha		
	CZ	WO 01/70729-A1	09-27-2001	Sanofi-Sythelabo		
	DA	WO 01/97808-A1	12-27-2001	Smithkline Beecham PLC		
	DB	WO 02/34242-A2	05-02-2002	Probiodrug AG		
	DC	WO 02/34243-A2	05-02-2002	Probiodrug AG		
	DD	WO 02/083109-A1	10-24-2002	Ferring BV		
	DE	JP 2002/338466	11-27-2002	Tanabe Seiyaku Co Ltd		
	DF	WO 03/002593-A2	01-09-2003	Probiodrug AG		
	DG	WO 03/002595-A2	01-09-2003	Probiodrug AG		
	DH	WO 03/002596-A2	01-09-2003	Probiodrug AG		
	DI	WO 03/016335-A2	02-27-2003	Probiodrug AG		
	DJ	WO 03/022871-A2	03-20-2003	Probiodrug AG		
	DK	WO 03/026652-A1	04-03-2003	Bristol-Myers Squibb Company		
	DL	WO 03/030946-A1	04-17-2003	Novartis AG		
	DM	WO 03/033524-A2	04-24-2003	Probiodrug AG		
	DN	JP 2003/128551	05-08-2003	Sankyo Co LTD		
	DO	WO 03/040174-A2	05-15-2003	Probiodrug AG		
	DP	WO 03/045228-A2	06-05-2003	Trustees of Tufts College		
	DQ	WO 03/045977-A2	06-05-2003	Trustees of Tufts College		
	DR	WO 03/048081-A2	06-12-2003	Bristol-Myers Squibb Company		
	DS	WO 03/048158-A1	06-12-2003	Bristol-Myers Squibb Company		
	DT	WO 03/057200-A2	07-17-2003	Novo Nordisk		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 10

Complete if Known	
Application Number	10/809,636
Filing Date	March 24, 2004
First Named Inventor	Jun Feng
Group Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	SYR-DPP-IV-5004-C1

	DU	WO 03/063903-A2	08-07-2003	Probiodrug AG		
	DV	WO 03/072556-A1	09-04-2003	Probiodrug AG		
	DW	WO 03/082898-A2	10-09-2003	Probiodrug AG		
	DX	WO 03/092605-A2	11-13-2003	Trustees of Tufts College		
	DY	WO 03/099279-A1	12-04-2003	Novartis AG		
	DZ	WO 03/099818-A1	12-04-2003	Chiron Corporation		
	EA	WO 03/106416-A2	12-24-2003	Smithkline Beecham Corporation		
	EB	WO 2004/017989-A1	03-04-2004	Probiodrug AG		
	EC	JP 2004/99600-A	04-02-2004	Sankyo Co. Ltd.		
	ED	WO 2004/031374-A2	04-15-2004	Probiodrug AG		
	EE	JP 2004/123738-A	04-22-2004	Takeda Chem Ind Ltd		
	EF	WO 2004/037176-A2	05-06-2004	Bristol-Myers Squibb Company		

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	EG	ARGAUD, DORIANE et al., Metaformin decreases gluconeogenesis by enhancing the pyruvate kinase flux in isolated rat hepatocytes, European J. Biochem. 213, 1341-1348 (1993).	
	EH	ASHCROFT, STEPHEN J.H. et al., Structure-activity relationships of alloxan-like compounds derived from uric acid, Br. J. Pharmac. (1986), 89 pp. 469-472.	
	EI	BAL, GUNTHER, Dipeptidyl Peptidase IV and Prolyl Oligopeptidase: Design, Synthesis and Evaluation of Substrates and Inhibitors, (2002) Universiteit Antwerpen.	
	EJ	BARAKAT, S.E.S., Synthesis and hypoglycemic activity of some new 3-[4- [[[(cyclohexylamino) carbonyl] amino]sulfony]phenyl]-4(3H)-quinazolinones, Az. J. Pharm. Sci., Vol. 25, (2000), pp. 48-57.	
	EK	BARAKAT, S.E.S., Synthesis and Hypoglycemic Activity of Some New 4(3H) -Quinazolinone Analogues, Saudi Pharmaceutical Journal, Vol. 8, No.4 (2000) pp.198-204.	
	EL	BAKER, B.R. et al., Irreversible Enzyme Inhibitors. On the Mode of Pyrimidine Binding of 5-alkyl and 5-Arylpyrimidines to Dihydrofolic Reductase (1,2), Journal of Heterocyclic Chemistry Vol. 4 (1967) pp. 39-48.	
	EM	BELGODERE, ELENA et al., Synthesis of Substituted Pyrimidines, Study of the Structure and of the Tautomeric Equilibria, (1976) Chem. Abstracts, Columbus, OH Vol. 85 No. 9.	
	EN	BEZUGLYI, P.O. et al., Synthesis of arylsulfonyl hydrazide of 3-R-quinazolone-4-carbonyl-2-acid, Pharmaceutical Journal (1979), pp. 70-71.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 10

Complete if Known	
Application Number	10/809,636
Filing Date	March 24, 2004
First Named Inventor	Jun Feng
Group Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	SYR-DPP-IV-5004-C1

	EO	BHADURI, A.P. et al., Urinary Metabolite of 2-Piperazino-3 (H)-4-Quinazolone (Centpiperalone), A Potent Blood Sugar Lowering Agent, Indian J. Biochem. Biophys., Vol. 12 (1975), pp. 413-414.	
	EP	BOURAS, MOHAMMED, et al., Metabolism of enterostatin in rat intestine, brain, membranes and serum: differential involvement of proline-specific peptidases, Peptides, Vol. 16, No. 3, (1995), pp. 399-405.	
	EQ	BRUN, JEAN-FREDERIC, et al., Effects of Oral Zinc Gluconate on Glucose Effectiveness and Insulin Sensitivity in Humans, Biological Trace Element Research Vol. 47 (1995), pp. 385-391.	
	ER	BUCKLEY, DI, Analysis of the Degradation of Insulinotropin [GLP-1 (7-37)] In Human Plasma and Production of Degradation Resistant Analogs.	
	ES	CHATTERJEE, A.K. et al., Effect of Centpiperalone in Insulin Deficient Diabetes, Indian Journal of Experimental Biology Vol. 18 (1980), pp. 1005-1008.	
	ET	CHATTERJEE, A.K. et al., Effect of Centpiperalone, a New Hypoglycemic Agent on Insulin Biosynthesis & Release from Isolated Pancreatic Islets of Rat, Indian Journal of Experimental Biology Vol. 20 (1981) pp.270-272.	
	EU	COPPOLA, GARY M. et al., 1-Aminomethylisoquinoline-4-carboxylates as Novel Dipeptidylpeptidase IV Inhibitors, Bioorganic & Medicinal Chemistry Letters Vol. 10 (2000), pp. 1555-1558.	
	EV	DEACON, CAROLYN F. et al., Degradation of Glucagon-Like Peptide 1 *in Vitro* Yields an N-Terminally Truncated Peptide That is a Major Endogenous Metabolite *in Vivo*, Journal of Clinical Endocrinology and Metabolism Vol. 80, No. 3 (1995), pp. 952-957.	
	EW	DEACON, CAROLYN F. et al., Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH_2-Terminus in Type II Diabetic Patients and in Healthy Subjects, Diabetes, Vol. 44 (1996), pp. 1125-1131.	
	EX	DEACON, CAROLYN F. et al., Dipeptidyl peptidase IV Inhibition Influences GLP-1 Metabolism in Vivo, Regulatory Peptides Vol. 64 Issues 1-3 (1996) p.30.	
	EY	DEACON, CAROLYN F. et al., Dipeptidyl peptidase IV Inhibition Potentiates the Insulinotropic Effect of Glucagon-Like Peptide 1 in the Anesthetized Pig, Diabetes, Vol. 47 (1998), pp. 764-769.	
	EZ	DEACON, CAROLYN F. et al., Dipeptidyl peptidase IV Inhibition as an Approach to the Treatment and Prevention of Type 2 Diabetes: a Historical Perspective, Biochemical and Biophysical Research Communications 294 (2002), pp. 1-4.	
	FA	DEMUTH, HANS-ULRICH et al., Rebuttal to Deacon and Holst: "Metaformin effects on depeptidyl peptidase IV degradation of glucagons-like peptide-1" versus "dipeptidyl peptidase inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective" Biochemical and Biophysical Research Communications 296 (2002) pp. 229-232.	
	FB	ENGEL, MICHAEL et al., The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism, Proc. Nat. Acad. Sci. Early Edition (2003), pp. 1-6.	
	FC	FANTUS, I. GEORGE, et al., Mechanism of Action of Metformin: Insulin Receptor and Postreceptor Effects in Vitro and in Vivo, J. Clinical Endocrinology & Metabolism (1986), pp. 898-905.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 10

Complete if Known	
Application Number	10/809,636
Filing Date	March 24, 2004
First Named Inventor	Jun Feng
Group Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	SYR-DPP-IV-5004-C1

	FD	GARRATT, PETER J. et al., A Novel Synthesis of Dihydropyrimidines, J. Chem. Soc., Chem. Commun. (1987), pp.568-569.	
	FE	GARRATT, PETER J. et al., One-Carbon Compounds as Synthetic Intermediates. The Synthesis of Hydropyrimidines and Hydroquinazolines by Sequential Nucleophilic Addition to Diphenyl Cyanocarbonimidate With Concomitant Cyclization, J. Org. Chem. (1988), pp. 1062-1069.	
	FF	GAZIT, AVIV et al., Tyrphostins IV – Highly Potent Inhibitors of EGF Receptor Kinase. Structure-Activity Relationship Study of 4- Anilidoquinazolines, Bioorganic & Medicinal Chemistry, Vol. 4, No.8 (1996) pp. 1203-1207.	
	FG	GUERRIERI, N., et al., Vanadium Inhibition of Serine and Cysteine Proteases, Comparative Biochemistry and Physiology Part A 122 (1997), pp.331-336.	
	FH	GUPTA, C.M. et al., Drugs Acting on the Central Nervous System. Syntheses of Substituted Quinazolones and Quinazolines and Triazepino-and Triazocionquinazolones, Division of Medicinal Chemistry, Central Drug Research Institute, Lucknow, India (1968), pp. 392-395.	
	FI	GUPTA, C.M. et al., New Potent Blood Sugar Lowering Compound, Nature, Vol. 223 (1969), p. 524.	
	FJ	GUPTA, C.M. et al., A Novel Class of Hypoglycaemic Agents: Syntheses & SAR in 2-Substituted 4(3H)-Quinazolones, 2-Substituted 4-Hydroxypolymethylene 5,6]pyrimidines & 3-Substituted 4-Oxo-pyrido [I,2-a] pyrimidines, Indian Journal of Chemistry, Vol. 9 (1971), pp. 201-206.	
	FK	HERMECZ, ISTVAN et al., Pyrido[1,2-a]Pyrimidines; New Chemical Entities in Medicinal Chemistry, Medicinal Research Reviews, Vol. 8, No. 2 (1988) pp.203-230.	
	FL	HINKE, SIMON A. et al., Metaformin Effects on Dipeptidylpeptidase IV Degradation of Glucagon-like Peptide-1, Biochemical and Biophysical Research Communications, 291 (2002) pp. 1302-1308.	
	FM	HINKE, SIMON A. et al., On Combination Therapy of Diabetes With Metaformin and Dipeptidyl Peptidase IV Inhibitors, Diabetes Care, Vol. 25, No. 8 (2002) pp. 1490-1492.	
	FN	HOLZ, GEORGE G. et al, Pancreatic Beta-Cells are Rendered Glucose-Competent by the Insulinotropic Hormone Glucagon-Like Peptide-1(7-37), Nature, Vol. 361 (1993), pp. 362-365.	
	FO	KHALID, NORAINI M., et al., Purification and Partial Characterization of a Prolyl-Dipeptidyl Aminopeptidase From Lactobacillus helveticus CNRZ 32, Applied and Environmental Microbiology (1990), pp. 381-388.	
	FP	KIEFFER, TIMOTHY J. et al., Degradation of Glucose-Dependant Insulinotropic Polypeptide and Truncated Glucagon-Like Peptide 1 in Vitro and in Vivo by Dipeptidyl Peptidase IV, Endocrinology, Vol. 136, No. 8 (1995) 3585-3596.	
	FQ	KIMURA, TOSHIKIRO et al., Oral Administration of Insulin as Poly(Vinyl Alcohol)-Gel Spheres in Diabetic Rats, Biological & Pharmaceutical Bulletin, Vol. 19, No. 6 (1996), 897-900.	
	FR	KOREEDA, YUJI et al., Isolation and Characterization of Dipeptidyl Peptidase IV From *Prevotella loescheii* ATCC 15930, Archives of Oral Biology, 46 (2001), 759-766.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 7 of 10

Complete if Known	
Application Number	10/809,636
Filing Date	March 24, 2004
First Named Inventor	Jun Feng
Group Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	SYR-DPP-IV-5004-C1

	FS	KUSAR, MIHAEL et al., Diethyl *N,N*-Dimethylaminomethylenemalonate in the Synthesis of Fused Heterocyclic Systems, Heterocyclic Chem. 33 (1996) pp. 1041-1046.	
	FT	LI JINPING, et al., Permolybdate and Pertungstate—Potent Stimulators of Insulin Effects in Rat Adipocytes: Mechanism of Action, Biochemistry, 34 (1995) 6218-6225.	
	FU	LIN, JIAN, Total Synthesis and Biological Evaluation of Fluoroolefin-containing Dipeptidyl Isosteres as Inhibitors of Dipeptidyl Peptidase IV (CD26), Dissertation presented to State University of New York at Albany, Department of Chemistry (1998).	
	FV	LOESER, ERIC et al., Selective *N*-Alkylation of Primary Amines with Chloroacetamides Under pH-Controlled Aqueous Conditions, Synthetic Communications, 32(3) (2002) pp. 403-409.	
	FW	MANNUCCI, EDUARDO, et al., Effect of Metaformin on Glucagon-Like Peptide-1 (GLP-1) and Leptin Levels in Obese Nondiabetic Subjects, Diabetes Care, Vol. 24, No. 3 (2001) 489-494.	
	FX	MENTLEIN, ROLF et al., Dipeptidyl-Peptidase IV Hydrolyses gastric Inhibitory Polypeptide, Glucagon-Like Peptide-1(7-36)amide, Peptide Histidine Methionine and is Respoinsible for Their Degradation in Human Serum, Eur. J. Biochem, Vol. 214, 829-835 (1991).	
	FY	MEYEROVITCH, JOSEPH et al., Oral Administration of Vanadate Normalizes Blood Glucose Levels in Streptozotocin-Treated Rats, The Journal of Biological Chemistry, Vol. 262, No. 14 (1987) 6658-6662.	
	FZ	MALLOY, J. ARDILL et al., Effect of Metaformin Treatment on Gastric Acid Secretion Gastrointestinal Hormone Levels in Normal Subjects, Diabetologia, Vol. 19 (1980) 93-96.	
	GA	MUKERJEE, S.S. et al., Effect of 2-piperazino-4(3H)-quinazolinone monoacetate on the tissue respiration, glucose uptake and lactic acid production by rat hemidiaphragm, Biochemical Pharmacology, Vol. 23 (1974) 3066-3067.	
	GB	MUKERJEE, S.S. et al., Studies on the Mechanism of Centpiperalone-Induced Hypoglycemia, Acta Diabet. Lat 13, 8 (1976) p 8.	
	GC	MUKERJEE, S.S. et al., Chronic Toxicity Studies of a Hypoglycemic Compound: Centpiperalone in Rats & Rhesus Monkeys, Indian Journal of Experimental Biology, Vol. 17 (1979) pp. 1346-1349.	
	GD	MUKERJEE, S.S. et al., Tissue Distribution of [^{3}H]Centpiperalone after Oral Administration, Indian J. Biochem. Biophys., Vol. 17 (1980) pp. 399-401.	
	GE	MUKHERJEE, SURATH K. et al., A novel hypoglycemic compound, Biochemical Pharmacology, Vol. 22 (1972) pp. 1529-1531.	
	GF	MUKHERJEE, SURATH K. et al., Effect of 2-piperazino-4(3H)-quinazolinone monoacetate on some aspects of carbohydrate metabolism of albino rats, Biochemical Pharmacology, Vol. 22 (1973) pp. 2205-2206.	
	GG	MUKHERJEE, SURATH K. et al., Studies on the Metabolic Changes Induced by a Synthetic Insulinogenic Agent, Ind. J. Physiol. & Allied Sci., Vol. 30, No. 3 (1976) pp. 105-116.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 8 of 10

Complete if Known	
Application Number	10/809,636
Filing Date	March 24, 2004
First Named Inventor	Jun Feng
Group Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	SYR-DPP-IV-5004-C1

	GH	MUKHERJEE, SURATH K. et al., Influence of Timing Oral Dosing of a Novel Hypoglycaemic Agent A-4166 in Relation to Food, Diabetologia Vol. 38 A194 Supplement 1 (1995).	
	GI	MUKHERJEE, Subal S. et al., Studies on the Mechanism of Centpiperalone-Induced Hypoglycemia, Acta Diabet. Lat. 13, 8, (1976) pp. 8-19.	
	GJ	MURTHY, G. RAMA et al., New Hypoglycemic Agents: Part V – Synthesis & Hypoglycemic Activity of Some New 1-[[p-(4-OXO-2-Methyl/Phenyl-3 (4H)-Quinazolinyl) Phenyl]] 3-Aryl-2-Ureas, Indian Drugs, 25 (1) (1987) pp. 19-22.	
	GK	MURTHY, G. RAMA et al., New Hypoglycemic Agents: Synthesis and Hypogylcemic Activity of Some New 1-{{*p*-(4-OXO-2-Substituted-3(4H)-Quinazolinyl)-Phenyl} Sulphonyl]-3-Aryl/Cyclohexyl-2-Thioureas, Current Science, Vol. 56, No. 24 (1987) pp. 1263-1265.	
	GL	NAKAMURA, SEIJI, et al., Effect of Chronic Vanadate Administration in Partially Depancreatized Rats, Diabetes Research and Clinical Practice 27 (1995) pp. 51-59. (Abstract Only)	
	GM	OHKUBO, I., et al., Dipeptidyl Peptidase IV From Porcine Seminal Plasma: Purification, Characterization, and N-Terminal Amino Acid Sequence, J. Biochem. (Tokyo) (1994) 116(5) pp. 1182-11826.	
	GN	PANDEYA, S.N. et al., Synthesis of Some New Amidine Derivatives As Potent Hypoglycemic Agents, Pharmacological Research Communications, Vol. 17, No.8 (1985) pp. 699-709.	
	GO	PAULY, R.P. et al., Inhibition of Dipeptydyl Peptidase IV (DPIV) in Rat Results in Improved Glucose Tolerance, Regulatory Peptides Vol. 64, Issues 1-3 (1996) p. 148.	
	GP	PEDERSON, RAYMOND A. et al., Improved Glucose Tolerance in Zucker Fatty Rats by Oral Administration of the Dipeptidyl Peptidase IV Inhibitor Isoleucine Thiazolide, Diabetes, Vol. 47 (1998) pp.1253-1258.	
	GQ	PILLAI, SREEKUMAR et al., Effects of ATP, Vanadate, and Molybdate on Cathepsin D-catalyzed Proteolysis, The Journal of Biological Chemistry, Vol. 280, No. 14 (1985) pp. 8384-9.	
	GR	PODANYI, BENJAMIN et al., Nitrogen Bridgehead Compounds. 62. Conformational Analysis of 6, 7, 8, 9-Tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-ones and Their Methyl Derivatives by NMR Spectroscopy, J. Org. Chem. 51 (1985) 394-399.	
	GS	POJE, M. et al., Diabetogenic action of allozan-like derivatives of uric acid, Experentia 36 (1980) pp. 78-9.	
	GT	POJE, M. et al., Oxidation of Uric Acid. 4. Synthesis, Structure, and Diabetogenic Action of *5*-Imino-*2,4,6* (*1*H,*3*H,*5*H)-pyrimidinetrione Salts and Their Alloxan-like Covalent Adducts, J. Med. Chem. 26 (1983) 861-4.	
	GU	POLACEK, I. et al., Hypoglycemic Activity of Amine Derivatives, Arzneim.-Forsch./ Drug Res. 28 (1978), 791-93.	
	GV	PRIDAL, L. et al., Glucagon-Like Peptide-1(7-37) Has a Larger Volume of Distribution Than Glucagon-Like Peptide1(7-36)amide in Dogs and is Degraded More Quickly in Vitro by Dog Plasma, European Journal of Drug Metabolism and Pharmacokinetics, Vol. 21 (1995), pp. 51-59.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 9 of 10

Complete if Known	
Application Number	10/809,636
Filing Date	March 24, 2004
First Named Inventor	Jun Feng
Group Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	SYR-DPP-IV-5004-C1

	GW	RAM, VISHNU JI et al., Synthesis and Antihyperglycemic Activity of Suitably Functionalized 3H-quinazolin-4-ones, Bioorganic & Medicinal Chemistry 11 (2003), pp. 2439-2444.	
	GX	SAWYER, JAMES H. et al., Pyrido[1,2-a]pyrimidinium Salts. Part 1. Synthesis from 2- Aminopyridines and Interconversion with 2-(2-Acylvinylamino) pyridines, J.C.S. Perkin I (1972), 1138-1143.	
	GY	SAXENA, A.M. et al., Mode of action of three structurally different hypoglycemic agents: A comparative study, Indian Journal of Experimental Biology, Vol. 34 (1996), pp. 351-355.	
	GZ	SEDO, ALEKSI et al., Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities? Biochimica et Biophysica Acta 1550 (2001), pp. 107-116.	
	HA	SEKIYA, T. et al., Pyrimidine derivatives. III (1) Synthesis of hypoglycemic 4-alkoxy-2-piperazino-activity of 6-polymethylenepyrmidines, Eur. J. Med. Chem. (1982), 75-79.	
	HB	SENTEN, KRISTEL et al., Development of Potent and Selective Dipeptidyl Peptidase II Inhibitors, Bioorganic & Medicinal Chemistry Letters 12 (2002) pp. 2825-2828.	
	HC	SETH, M. et al., Syntheses of 2-Substituted & 2,3-Distributed 4(3H)-Quinazolones, Indian Journal of Chemistry, Vol. 14B (1975), 536-540.	
	HD	SHIMAZAWA, RUMIKO et al., Novel Small Molecule Nonpeptide Aminopeptidase N Inhibitors with A Cyclic Imide Skeleton, J. Enzyme Inhibition, Vol. 14 (1999) pp. 259-275.	
	HE	SHISHEVA, ASSIA, et al., Insulinlike Effects of Zinc Ion in Vitro and in Vivo; Preferential Effects on Desensitized Adipocytes and Induction of Normoglycemia in Streptozocin-Induced Rats, Diabetes, Vol. 41 (1992), pp. 982-988.	
	HF	SINYAK, R. S. et al., Synthesis and Biological Properties of Derivatives of 4-Heterylmercaptoquinazoline, Translated from Khimiko-farmatsevticheskii Zhurnal, Vol. 20, No. 2, pp 168-171 (1986), pp. 103-105.	
	HG	SOKAL, JOSEPH E., Basal Plasma Glucagon Levels of Man, Journal of Clinical Investigation, Vol. 46, No.5 (1967) pp. 778-785.	
	HH	SRIVASTAVA, P.P. et al., Efficacy of Centpiperalone in Combination With Biguanide & Sulfonylurea, Indian Journal of Experimental Biology, Vol. 21 (1983), pp. 390-392.	
	HI	TANAKA, KEIJI et al, Vanadate Inhibits the ATP-Dependant Degradation of Proteins in Reticulocytes Without Affecting Ubiquitin Conjugation, The Journal of Biological Chemistry, Vol. 259, No. 4 (1983), 2803-2809.	
	HJ	VILLHAUER, EDWIN B. et al., DPP-IV Inhibition and Therapeutic Potential, Annual Reports in Chemistry 36 (2001), 191-200.	
	HK	VILLHAUER, EDWIN B. et al., 1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(*S*)-pyrrolidine: A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties, J. Med. Chem. 46 (2003), pp. 2774-2789.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 10 of 10

Complete if Known	
Application Number	10/809,636
Filing Date	March 24, 2004
First Named Inventor	Jun Feng
Group Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	SYR-DPP-IV-5004-C1

	HL	WELLS, CAROL L. et al., Role of Anaerobic Flora in the Translocation of Aerobic and Facultatively Anaerobic Intestinal Bacteria, Infection and Immunity, Vol. 55, No. 11 (1987) pp. 2689-94.	
	HM	WIEDEMAN, PAUL E. et al., Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes, Current Opinion in Investigational Drugs, Vol. 4, No. 4 (2003), pp. 412-420.	
	HN	YASUDA, NOBUYUKI et al. Enhanced Secretion of Glucagon-Like Peptide 1 by Biguanide Compounds, Biochemical and Biophysical Research Communications 298 (2002), pp. 779-784.	
	HO	YUEN, V.G. et al., Acute and Chronic Oral Administration of Bis(maltolato)oxovanadium(IV) in Zucker Diabetic Fatty (ZDF) Rats, Diabetes Research and Clinical Practice 43 (1999), pp. 9-19.	
	HP	ZANDER, METTE, et al., Additive Glucose-Lowering Effects of Glucagon-Like Peptide-1 and Metformin in Type 2 Diabetes, Diabetes Care, Vol. 24, No. 4 (2001) pp. 720-725.	
	HQ	ZHANG, ANQI et al., Vanadate Stimulation of Insulin Release in Normal Mouse Islets, The Journal of Biological Chemistry, Vol. 266, No. 32 (1991), pp. 21649-56.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.